Literature DB >> 22930729

Genome-wide DNA methylation events in TMPRSS2-ERG fusion-negative prostate cancers implicate an EZH2-dependent mechanism with miR-26a hypermethylation.

Stefan T Börno1, Axel Fischer, Martin Kerick, Maria Fälth, Mark Laible, Jan C Brase, Ruprecht Kuner, Andreas Dahl, Christina Grimm, Behnam Sayanjali, Melanie Isau, Christina Röhr, Andrea Wunderlich, Bernd Timmermann, Rainer Claus, Christoph Plass, Markus Graefen, Ronald Simon, Francesca Demichelis, Mark A Rubin, Guido Sauter, Thorsten Schlomm, Holger Sültmann, Hans Lehrach, Michal R Schweiger.   

Abstract

UNLABELLED: Prostate cancer is the second most common cancer among men worldwide. Alterations in the DNA methylation pattern can be one of the leading causes for prostate cancer formation. This study is the first high-throughput sequencing study investigating genome-wide DNA methylation patterns in a large cohort of 51 tumor and 53 benign prostate samples using methylated DNA immunoprecipitation sequencing. Comparative analyses identified more than 147,000 cancer-associated epigenetic alterations. In addition, global methylation patterns show significant differences based on the TMPRSS2-ERG rearrangement status. We propose the hypermethylation of miR-26a as an alternative pathway of ERG rearrangement-independent EZH2 activation. The observed increase in differential methylation events in fusion-negative tumors can explain the tumorigenic process in the absence of genomic rearrangements. SIGNIFICANCE: In contrast to TMPRSS2-ERG -rearranged tumors, the pathomechanism for gene fusion-negative tumors is completely unclear. Using a sequencing-based approach, our work uncovers significant global epigenetic alterations in TMPRSS2-ERG gene fusion-negative tumors and provides a mechanistic explanation for the tumor formation process. ©2012 AACR.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22930729     DOI: 10.1158/2159-8290.CD-12-0041

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  56 in total

Review 1.  [Novel preclinical models and biomarkers for prostate cancer].

Authors:  N Korzeniewski; M Tapia-Laliena; Y Tolstov; S Pahernik; B Hadaschik; M Hohenfellner; S Duensing
Journal:  Urologe A       Date:  2013-09       Impact factor: 0.639

2.  Molecular Evolution of Early-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical Trajectories.

Authors:  Clarissa Gerhauser; Francesco Favero; Thomas Risch; Ronald Simon; Lars Feuerbach; Yassen Assenov; Doreen Heckmann; Nikos Sidiropoulos; Sebastian M Waszak; Daniel Hübschmann; Alfonso Urbanucci; Etsehiwot G Girma; Vladimir Kuryshev; Leszek J Klimczak; Natalie Saini; Adrian M Stütz; Dieter Weichenhan; Lisa-Marie Böttcher; Reka Toth; Josephine D Hendriksen; Christina Koop; Pavlo Lutsik; Sören Matzk; Hans-Jörg Warnatz; Vyacheslav Amstislavskiy; Clarissa Feuerstein; Benjamin Raeder; Olga Bogatyrova; Eva-Maria Schmitz; Claudia Hube-Magg; Martina Kluth; Hartwig Huland; Markus Graefen; Chris Lawerenz; Gervaise H Henry; Takafumi N Yamaguchi; Alicia Malewska; Jan Meiners; Daniela Schilling; Eva Reisinger; Roland Eils; Matthias Schlesner; Douglas W Strand; Robert G Bristow; Paul C Boutros; Christof von Kalle; Dmitry Gordenin; Holger Sültmann; Benedikt Brors; Guido Sauter; Christoph Plass; Marie-Laure Yaspo; Jan O Korbel; Thorsten Schlomm; Joachim Weischenfeldt
Journal:  Cancer Cell       Date:  2018-12-10       Impact factor: 31.743

3.  Epigenomic alterations in localized and advanced prostate cancer.

Authors:  Pei-Chun Lin; Eugenia G Giannopoulou; Kyung Park; Juan Miguel Mosquera; Andrea Sboner; Ashutosh K Tewari; Levi A Garraway; Himisha Beltran; Mark A Rubin; Olivier Elemento
Journal:  Neoplasia       Date:  2013-04       Impact factor: 5.715

4.  Distinct epigenetic mechanisms distinguish TMPRSS2-ERG fusion-positive and -negative prostate cancers.

Authors:  Joshi J Alumkal; James G Herman
Journal:  Cancer Discov       Date:  2012-11       Impact factor: 39.397

Review 5.  An arranged marriage for precision medicine: hypoxia and genomic assays in localized prostate cancer radiotherapy.

Authors:  R G Bristow; A Berlin; A Dal Pra
Journal:  Br J Radiol       Date:  2014-02-03       Impact factor: 3.039

6.  Epigenomic profiling of DNA methylation in paired prostate cancer versus adjacent benign tissue.

Authors:  Milan S Geybels; Shanshan Zhao; Chao-Jen Wong; Marina Bibikova; Brandy Klotzle; Michael Wu; Elaine A Ostrander; Jian-Bing Fan; Ziding Feng; Janet L Stanford
Journal:  Prostate       Date:  2015-09-18       Impact factor: 4.104

7.  The heritability of prostate cancer in the Nordic Twin Study of Cancer.

Authors:  Jacob B Hjelmborg; Thomas Scheike; Klaus Holst; Axel Skytthe; Kathryn L Penney; Rebecca E Graff; Eero Pukkala; Kaare Christensen; Hans-Olov Adami; Niels V Holm; Elizabeth Nuttall; Steinbjorn Hansen; Mikael Hartman; Kamila Czene; Jennifer R Harris; Jaakko Kaprio; Lorelei A Mucci
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-05-08       Impact factor: 4.254

8.  MiR-26a and miR-138 block the G1/S transition by targeting the cell cycle regulating network in prostate cancer cells.

Authors:  Kati Erdmann; Knut Kaulke; Christiane Rieger; Karsten Salomo; Manfred P Wirth; Susanne Fuessel
Journal:  J Cancer Res Clin Oncol       Date:  2016-08-25       Impact factor: 4.553

9.  Loss of miR-26a-5p promotes proliferation, migration, and invasion in prostate cancer through negatively regulating SERBP1.

Authors:  Kai Guo; Shaobo Zheng; Yawen Xu; Abai Xu; Binshen Chen; Yong Wen
Journal:  Tumour Biol       Date:  2016-07-23

Review 10.  Minireview: the molecular and genomic basis for prostate cancer health disparities.

Authors:  Isaac J Powell; Aliccia Bollig-Fischer
Journal:  Mol Endocrinol       Date:  2013-04-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.